10:07 AM EDT, 06/05/2025 (MT Newswires) -- ImmunoPrecise Antibodies ( IPA ) said Thursday it discovered a "highly conserved epitope" in all four dengue virus serotypes using its LENSai platform.

The discovery identified a part of the virus, known as an epitope, that is "unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus," the company said.

The discovery is a "major milestone toward the development of a potential universal dengue vaccine," ImmunoPrecise said.

The company said it plans to expand its vaccine design platform to other infectious diseases like HIV, Norovirus, as well as an improved RSV vaccine. Also, early-stage evaluations are underway to explore the use of the platform in oncology, it said.

The company's shares were rising past 13% in recent trading.

Price: 0.62, Change: +0.05, Percent Change: +8.09